Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1619
This examiner grants 36% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18256943 | MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18538022 | BIODEGRADABLE COMPACTED FORMULATIONS AND METHODS OF USE AND MANUFACTURE THEREOF | Non-Final OA | Purdue Research Foundation |
| 18516295 | Softgel Capsule and Method of Marking a Softgel Capsule | Non-Final OA | R.P. Scherer Technologies, LLC |
| 18315330 | BIOMIMETIC ARTIFICIAL CELLS: ANISOTROPIC SUPPORTED LIPID BILAYERS ON BIODEGRADABLE MICRO AND NANOPARTICLES FOR SPATIALLY DYNAMIC SURFACE BIOMOLECULE PRESENTATION | Final Rejection | The Johns Hopkins University |
| 18187526 | CHEMICAL COMPOSITION | Non-Final OA | The Johns Hopkins University |
| 19173475 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | Final Rejection | NACUITY PHARMACEUTICALS, INC. |
| 19169817 | USE OF VARENICLINE FOR TREATING OCULAR CONDITIONS | Final Rejection | Oyster Point Pharma, Inc. |
| 18399465 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | ThermoLife International, LLC |
| 18399664 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | ThermoLife International, LLC |
| 18399668 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | ThermoLife International, LLC |
| 18399677 | ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | ThermoLife International, LLC |
| 19018403 | Soft Chews with Low Water Activity and Methods of Manufacturing Same | Non-Final OA | Florida Research Group, LLC |
| 18009095 | MICROENCAPSULATED ORAL STERNE VACCINE | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 17941129 | FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF | Non-Final OA | SAWAI PHARMACEUTICAL Co., Ltd. |
| 18552211 | COATED FAMOTIDINE PARTICLE | Final Rejection | Kenvue Brands LLC |
| 17530559 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18691949 | ANTI-AGING AGENT, COSMETIC PRODUCT, WET TOWEL, AND HYGIENE PRODUCT | Non-Final OA | VB JAPAN TECHNOLOGY CO., LTD. |
| 18588829 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | Non-Final OA | VIVIER CANADA INC. |
| 18686305 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | Non-Final OA | American Regent, Inc. |
| 18195239 | REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE | Final Rejection | Balchem Corporation |
| 18557535 | PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | QILU PHARMACEUTICAL CO., LTD. |
| 17340132 | Consumer Products with Improved Aesthetics | Final Rejection | INTERNATIONAL FLAVORS & FRAGRANCES INC. |
| 18264506 | UTIDELONE LIPOSOME COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | Chengdu Biostar Pharmaceuticals, LTD. |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | Non-Final OA | QUEEN MARY UNIVERSITY OF LONDON |
| 17555908 | METHODS AND COMPOSITIONS FOR THE PROTECTION OF HAIR | Final Rejection | Gelest, Inc. |
| 18030541 | STABLE ORAL DISPERSIBLE FORMULATION FOR EPINEPHRINE | Final Rejection | Catalent U.K. Swindon Zydis Limited |
| 17796218 | PROCESS FOR PREPARING SOLID FORMULATIONS COMPRISING A HYDROPHOBIC COMPOUND DISPERSIBLE IN A COLD LIQUID AND RELATIVE SOLID FORMULATIONS | Final Rejection | BIOFARMA S.R.L. |
| 17623576 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | Final Rejection | DYNAMIC BIOLOGICS INC. |
| 17995768 | Compositions and Methods For Blood-Brain Barrier Delivery | Non-Final OA | Aliada Therapeutics, Inc. |
| 16628399 | IMPLANTABLE DEVICE | Final Rejection | Biotyx Medical (Shenzhen) Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy